Repurposing Selamectin as an Antimicrobial Drug against Hospital-Acquired <i>Staphylococcus aureus</i> Infections

The emergence of multidrug-resistant strains requires the urgent discovery of new antibacterial drugs. In this context, an antibacterial screening of a subset of anthelmintic avermectins against gram-positive and gram-negative strains was performed. Selamectin completely inhibited bacterial growth a...

Full description

Bibliographic Details
Main Authors: Veronica Folliero, Federica Dell’Annunziata, Biagio Santella, Emanuela Roscetto, Carla Zannella, Nicoletta Capuano, Alessandro Perrella, Anna De Filippis, Giovanni Boccia, Maria Rosaria Catania, Massimiliano Galdiero, Gianluigi Franci
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Microorganisms
Subjects:
Online Access:https://www.mdpi.com/2076-2607/11/9/2242
Description
Summary:The emergence of multidrug-resistant strains requires the urgent discovery of new antibacterial drugs. In this context, an antibacterial screening of a subset of anthelmintic avermectins against gram-positive and gram-negative strains was performed. Selamectin completely inhibited bacterial growth at 6.3 μg/mL concentrations against reference gram-positive strains, while no antibacterial activity was found against gram-negative strains up to the highest concentration tested of 50 μg/mL. Given its relevance as a community and hospital pathogen, further studies have been performed on selamectin activity against <i>Staphylococcus aureus</i> (<i>S. aureus</i>), using clinical isolates with different antibiotic resistance profiles and a reference biofilm-producing strain. Antibacterial studies have been extensive on clinical <i>S. aureus</i> isolates with different antibiotic resistance profiles. Mean MIC<sub>90</sub> values of 6.2 μg/mL were reported for all tested <i>S. aureus</i> strains, except for the macrolide-resistant isolate with constitutive macrolide-lincosamide-streptogramin B resistance phenotype (MIC<sub>90</sub> 9.9 μg/mL). Scanning Electron Microscopy (SEM) showed that selamectin exposure caused relevant cell surface alterations. A synergistic effect was observed between ampicillin and selamectin, dictated by an FIC value of 0.5 against methicillin-resistant strain. Drug administration at MIC concentration reduced the intracellular bacterial load by 81.3%. The effect on preformed biofilm was investigated via crystal violet and confocal laser scanning microscopy. Selamectin reduced the biofilm biomass in a dose-dependent manner with minimal biofilm eradication concentrations inducing a 50% eradication (MBEC<sub>50</sub>) at 5.89 μg/mL. The cytotoxic tests indicated that selamectin exhibited no relevant hemolytic and cytotoxic activity at active concentrations. These data suggest that selamectin may represent a timely and promising macrocyclic lactone for the treatment of <i>S. aureus</i> infections.
ISSN:2076-2607